Q4 2024 |
824 |
$894M |
+$99.3M |
-$155M |
-$55.7M |
USFR, ISRG, CAT, WWJD, ANET
|
13F-HR |
1/17/2025, 04:13 PM |
Q3 2024 |
827 |
$977M |
+$211M |
-$150M |
+$60.2M |
SMCI, IBD, CAT, USFR, ISRG
|
13F-HR |
10/10/2024, 03:44 PM |
Q2 2024 |
802 |
$868M |
+$93.1M |
-$171M |
-$78M |
IBD, USFR, CAT, ISRG, WWJD
|
13F-HR |
8/12/2024, 05:01 PM |
Q1 2024 |
787 |
$975M |
+$176M |
-$173M |
+$2.28M |
CAT, USFR, ISRG, IBD, PGR
|
13F-HR |
5/7/2024, 04:51 PM |
Q4 2023 |
785 |
$909M |
+$128M |
-$87.6M |
+$40.4M |
IBD, USFR, CAT, NOW, WWJD
|
13F-HR |
2/12/2024, 02:43 PM |
Q3 2023 |
791 |
$783M |
+$148M |
-$93.1M |
+$54.9M |
IBD, USFR, CAT, NOW, PLD
|
13F-HR |
10/26/2023, 11:59 AM |
Q2 2023 |
788 |
$827M |
+$130M |
-$92M |
+$38.5M |
IBD, USFR, ISRG, PLD, NOW
|
13F-HR |
7/31/2023, 10:23 AM |
Q1 2023 |
781 |
$785M |
+$116M |
-$75.4M |
+$40.4M |
USFR, IBD, PLD, ADI, NOW
|
13F-HR |
4/24/2023, 10:24 AM |
Q4 2022 |
743 |
$777M |
+$82.9M |
-$21.6M |
+$61.3M |
TFLO, USFR, IBD, WWJD, BLES
|
13F-HR |
1/26/2023, 01:28 PM |
Q3 2022 |
754 |
$708M |
+$138M |
-$94.2M |
+$43.4M |
USFR, TFLO, IBD, UUP, WWJD
|
13F-HR |
11/7/2022, 04:01 PM |
Q2 2022 |
762 |
$754M |
+$171M |
-$47.4M |
+$123M |
USFR, IBD, UUP, WWJD, BLES
|
13F-HR |
8/10/2022, 12:37 PM |
Q1 2022 |
788 |
$864M |
+$155M |
-$57M |
+$97.7M |
VGSH, IBD, PHYS, BLES, WWJD
|
13F-HR |
4/21/2022, 10:10 AM |
Q4 2021 |
785 |
$861M |
+$119M |
-$43.8M |
+$75.1M |
IBD, VGLT, ISRG, NOW, PLD
|
Restatement |
2/14/2022, 09:02 AM |
Q3 2021 |
794 |
$791M |
+$422M |
-$359M |
+$63.5M |
IBD, VGLT, ISRG, NOW, BLES
|
13F-HR |
11/9/2021, 02:02 PM |
Q2 2021 |
593 |
$760M |
+$113M |
-$48.6M |
+$64.7M |
NVDA, IBD, BLES, VGLT, ISMD
|
13F-HR |
8/10/2021, 04:58 PM |
Q1 2021 |
597 |
$652M |
+$237M |
-$75.9M |
+$161M |
NVDA, IBD, VGIT, BLES, ISMD
|
13F-HR |
4/30/2021, 12:07 PM |
Q4 2020 |
622 |
$452M |
+$140M |
-$42.1M |
+$97.9M |
IBD, BLES, NVDA, ISMD, WWJD
|
13F-HR |
2/12/2021, 01:47 PM |
Q3 2020 |
432 |
$363M |
+$119M |
-$17.7M |
+$102M |
VGIT, IBD, BLES, NVDA, WWJD
|
13F-HR |
11/16/2020, 03:27 PM |
Q2 2020 |
485 |
$290M |
+$60.3M |
-$25.1M |
+$35.2M |
IBD, BLES, WWJD, ISMD, BIBL
|
13F-HR |
8/12/2020, 03:46 PM |
Q1 2020 |
735 |
$250M |
+$76.5M |
-$34.9M |
+$41.5M |
IBD, BLES, WWJD, ISMD, BIBL
|
13F-HR |
5/8/2020, 04:44 PM |
Q4 2019 |
351 |
$279M |
+$20.3M |
-$14.5M |
+$5.83M |
IBD, BLES, ISMD, BIBL, WWJD
|
13F-HR |
1/24/2020, 11:28 AM |
Q3 2019 |
375 |
$262M |
+$38.7M |
-$3.4M |
+$35.3M |
IBD, BLES, ISMD, BIBL, UNP
|
13F-HR |
11/13/2019, 01:18 PM |
Q2 2019 |
328 |
$238M |
+$30M |
-$8.87M |
+$21.1M |
IBD, BLES, ISMD, BIBL, UNP
|
13F-HR |
7/16/2019, 01:32 PM |
Q1 2019 |
297 |
$215M |
+$56M |
-$4.65M |
+$51.3M |
IBD, BLES, ISMD, BIBL, ABBV
|
13F-HR |
5/16/2019, 07:42 AM |
Q4 2018 |
242 |
$149M |
+$14M |
-$1.03M |
+$13M |
BLES, IBD, ISMD, BIBL, ABBV
|
Restatement |
2/21/2019, 05:01 PM |
Q3 2018 |
237 |
$162M |
+$20.8M |
-$1.75M |
+$19M |
BLES, IBD, ISMD, BIBL, NVDA
|
Restatement |
2/21/2019, 04:59 PM |
Q2 2018 |
220 |
$141M |
+$42.1M |
-$489K |
+$41.6M |
BLES, IBD, ISMD, BIBL, ABBV
|
Restatement |
2/21/2019, 04:59 PM |
Q1 2018 |
199 |
$98.2M |
+$17.4M |
-$40.2K |
+$17.3M |
BLES, IBD, ISMD, BIBL, ITW
|
Restatement |
2/21/2019, 08:04 PM |
Q4 2017 |
869 |
$117M |
|
|
|
BLES, IBD, ISMD, BIBL, JNPR
|
Restatement |
2/21/2019, 04:49 PM |